CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The new online Learning Center with new content can still be found under the “Training” folder on ...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...